timothy sykes logo
Haemonetics (HAE) Stock Climbs After Citi Ups Price Target Thumbnail
G Google News

Haemonetics (HAE) Stock Climbs After Citi Ups Price Target

JACK KELLOGG•UPDATED OCT. 8, 2026, 3:02 PM ET
Reviewed by Tim Sykesand Fact-checked by Ellis Hobbs

Haemonetics Corporation stocks have been trading up by 16.93 percent, driven primarily by strong earnings and upbeat analyst upgrades

Key Takeaways

  • Citigroup upgraded Haemonetics from Neutral to Buy and raised its price target to $123, well above the prior analyst mean target near $108.40.
  • Shares of HAE jumped roughly 2.4% after the upgrade and target hike from $92 to $123, signaling fresh momentum with room for follow-through.
  • Citi is leaning on earnings upside from Haemonetics’ new non-exclusive CSL supply deal, estimating every 10% share recapture can add $0.13 to EPS.
  • The Vivasure acquisition is progressing, with an additional $6.1M milestone paid and up to $10M more in earnouts tied to future Vivasure-driven revenues.
  • Haemonetics set its Q2 FY2027 earnings release and call for 2026/11/05, a key checkpoint for updates on the CSL partnership and Vivasure integration.

Candlestick Chart

Live Update At 15:02:08 EDT: On Thursday, October 08, 2026 Haemonetics Corporation stock [NYSE: HAE] is trending up by 16.93%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

Haemonetics Corporation, ticker HAE, is acting like a steady climber that just hit a steeper part of the hill. On the daily chart, HAE spent the past few weeks grinding around $104–$109 before spiking to a $121 high and closing at $118.93. For short-term traders, that is a clear range breakout with confirmation.

Intraday, HAE opened near $115 and quickly pushed into the $120s before consolidating in a tight band around $118–$119. That intraday action shows strong dip-buying and controlled profit-taking instead of a blow-off top. Volume ran below average on the upgrade pop, which tells active traders this move is driven more by sentiment reset than by a full-blown crowd rush. That often leaves room for a second leg.

More Breaking News

Fundamentally, Haemonetics posted quarterly revenue of about $339.4M with gross margin near 59%, strong for a medical technology name. Net income from continuing operations was $33.0M, translating to diluted EPS of $0.72 and EBITDA of $84.6M. The balance sheet shows $223.4M in cash against roughly $1.17B in long-term debt, but leverage is cushioned by a 3.1 current ratio and solid interest coverage around 21.8 times. HAE trades at a rich 50x earnings and 3.5x sales, so the stock needs growth — and that is exactly what Citi’s thesis is leaning into.

Why Traders Are Watching HAE Now

The real spark for HAE this week is the Citigroup upgrade. Citigroup bumped Haemonetics from Neutral to Buy and lifted its price target from $92 to $123, well ahead of the prior mean target near $108.40. For traders, that is not just a routine tweak — it is a clear valuation reset. When a large desk steps out ahead of the Street like that, momentum and quant funds often take notice.

Citi’s call is anchored to something tangible: a new non-exclusive supply agreement between Haemonetics and CSL. The bank expects earnings upside from this deal and even gives a trading-style metric to frame it. Their estimate says every 10% share of business HAE wins back from CSL could add about $0.13 to EPS. For chart-focused traders, that is the kind of simple leverage number you can model against the current 50x P/E and see why a $123 target makes sense in their view.

The immediate tape action lines up. Haemonetics shares climbed roughly 2.4% on the day of the upgrade, pushing the stock from the low $100s into the high teens near $119. Yet volume came in below the daily average. That combination — a clean breakout on light participation — often means many funds and shorter-term traders have not fully repositioned yet. If HAE holds above former resistance around $108–$110 and builds a new base, breakout traders will be watching for a push toward that $123 zone Citi highlighted.

On top of the analyst action, HAE continues to advance its Vivasure strategy. The company’s acquisition of Vivasure triggered a fresh $6.1M milestone payment to Orchestra BioMed, completing $11M in initial consideration with up to $10M in additional earnouts wired to future Vivasure-related revenue. The milestone confirms that Vivasure’s PerQseal Elite bioabsorbable vessel closure system is tracking to plan, a quiet but important signal that Haemonetics is not just leaning on CSL for growth.

Conclusion

For traders scanning the healthcare space, Haemonetics Corporation is moving from a slow grinder to a stock with a clear story behind the chart. The breakout above the tight $104–$109 range, the push toward $120, and the fresh Buy rating with a $123 target give HAE a defined technical and narrative roadmap. Short-term players can anchor their levels around that prior range top, while swing traders can treat the Citi target as an upper reference, not a guarantee.

The fundamentals behind HAE — high gross margins, decent free cash flow around $44.4M last quarter, and a manageable debt load — support that story. The CSL agreement offers measurable EPS upside if Haemonetics wins back share, while the Vivasure earnouts tie future cash outlays directly to product success. The scheduled Q2 FY2027 earnings call on 2026/11/05 is the next date every serious HAE watcher should have on the calendar, because management commentary on CSL volumes and PerQseal progress will either confirm or pressure this new bull case.

Tim Sykes often says, “Trade like a sniper, not a machine gun — wait for the best setups, then strike fast and keep risk small.” That mindset lines up with a broader trading philosophy: as millionaire penny stock trader and teacher Tim Sykes, says, “Embrace the journey, the ups and downs; each mistake is a lesson to improve your strategy.”. For HAE, that means letting the stock prove it can hold the breakout, respecting the volatility around upgrades, and using clear levels instead of chasing headlines. This article is for educational and research purposes only and is not trading advice, but for disciplined traders, Haemonetics now belongs on the watchlist.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”